After this initial phase, your provider may recommend maintenance injections every month or every few months, depending on your ongoing needs
5-Amino-1MQ works by inhibiting NNMT (nicotinamide N-methyltransferase), an enzyme that depletes cellular NAD+ and SAM
Although clinical trials specifically for MASH have not yet been conducted, preclinical studies confirm significant regulatory effects on hepatic metabolism, providing a novel strategy for targeted MASH therapy and supporting future translational research
The injection should be given in the middle third of both axes
A provider needs to review medical history, current medications, and goals before recommending semaglutide, tirzepatide, or a supportive addition like B12 or NAD